Objective To refine the spectrum of anti-Ku-associated disease, a condition that is equivocally described by current diagnostic criteria for connective tissue diseases. Methods Among 42 consecutive patients harbouring anti-Ku antibodies, subgroups with similar phenotypes and prognosis were delineated without an a priori diagnosis using hierarchical clustering analysis of the cumulative clinico-biological features recorded during the follow-up. Features present at baseline that most efficiently predicted the outcomes were then identified using a sensitivity–specificity sum maximisation approach. Results Clinico-biological features were clustered into three groups. Glomerulonephritis and ILD, the two fatal complications in this cohort, were unequally distributed between the three clusters that additionally differed on six clinico-biological features. Among features present at baseline, elevated serum level of creatine kinase (CK) and anti-dsDNA antibodies were generally mutually exclusive and most efficiently predicted the cluster belonging at last follow-up. Anti-Ku patients with elevated CK had a 22-fold higher risk of ILD while anti-Ku patients with anti-dsDNA antibodies had a 13-fold higher risk of glomerulonephritis Conclusion “Anti-Ku with elevated CK” syndrome and “anti-Ku with anti-dsDNA” syndrome represent two distinct entities that are important to recognise in order to best tailor patient care.
1 September 2020 in Annals of the Rheumatic Diseases
Table 1 Myositis-specific and associated autoantibodies in our 15 patients with anti-Ku autoantibodies and elevated CK MSA and MAA Anti-Ku patients with elevated CK n=15 Anti-Jo1 0/15 Anti-PL7 0/13 Anti-PL12 0/13 Anti-OJ 0/9 Anti-EJ 0/9 Anti-Ha 0/9 Anti-Zo 0/9 Anti-KS 0/9 Anti-U1-RNP 0/15 Anti-PM/Scl 1/14 Anti-Mi2 0/12 Anti-MDA5 1/9 Anti-TIF1γ 2/9 Anti-NXP2 0/9 Anti-SAE 0/9 Anti-SRP 0/11 Anti-HMGCR 0/9 Total 2* *One patient was positive for both anti-MDA5 and anti-TIF1γ; another had anti-PM/scl and anti-TIF1γ. CK, creatine kinase; MAA, myositis-associated autoantibodies; MSA, myositis-specific autoantibodies.
1 October 2020 in Annals of the Rheumatic Diseases